Metagenome Data on Intestinal Phage-Bacteria Associations Aids the Development of Phage Therapy against Pathobionts.
Animals
Anti-Bacterial Agents
/ pharmacology
Bacteriophages
/ genetics
Clostridioides difficile
/ virology
Clostridium Infections
/ therapy
Disease Models, Animal
Endopeptidases
/ genetics
Feces
/ microbiology
Female
Gastrointestinal Microbiome
/ genetics
Genome, Bacterial
Genome, Viral
Humans
Metagenome
Mice
Mice, Inbred C57BL
Phage Therapy
/ methods
Prophages
/ genetics
Sequence Analysis, DNA
Specific Pathogen-Free Organisms
Viral Proteins
/ genetics
CRISPR
Clostridioides difficile infection
bacteriome
bacteriophage
host bacteria-phage association
metagenome analysis
prophage
virome
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
09 09 2020
09 09 2020
Historique:
received:
21
01
2020
revised:
12
05
2020
accepted:
10
06
2020
pubmed:
12
7
2020
medline:
26
5
2021
entrez:
12
7
2020
Statut:
ppublish
Résumé
The application of bacteriophages (phages) is proposed as a highly specific therapy for intestinal pathobiont elimination. However, the infectious associations between phages and bacteria in the human intestine, which is essential information for the development of phage therapies, have yet to be fully elucidated. Here, we report the intestinal viral microbiomes (viromes), together with bacterial microbiomes (bacteriomes), in 101 healthy Japanese individuals. Based on the genomic sequences of bacteriomes and viromes from the same fecal samples, the host bacteria-phage associations are illustrated for both temperate and virulent phages. To verify the usefulness of the comprehensive host bacteria-phage information, we screened Clostridioides difficile-specific phages and identified antibacterial enzymes whose activity is confirmed both in vitro and in vivo. These comprehensive metagenome analyses reveal not only host bacteria-phage associations in the human intestine but also provide vital information for the development of phage therapies against intestinal pathobionts.
Identifiants
pubmed: 32652061
pii: S1931-3128(20)30344-9
doi: 10.1016/j.chom.2020.06.005
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Viral Proteins
0
Endopeptidases
EC 3.4.-
endolysin
EC 3.4.99.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-389.e9Subventions
Organisme : NIAID NIH HHS
ID : R01 AI079145
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests The authors declare no competing interests.